Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to compare the relative bioavailability (rate and extent of
absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets
(by Berlex, Inc.) following a single, oral dose (2 x 3 mg/0.02 mg tablet) in healthy, adult
subjects administered under fasting conditions.